Am. J. Respir. Crit. Care Med., Volume 161, Number 6, June 2000, 1897-1901

The Effects of Oxitropium Bromide on Exercise Performance in Patients with Stable Chronic Obstructive Pulmonary Disease
A Comparison of Three Different Exercise Tests

TORU OGA, KOICHI NISHIMURA, MITSUHIRO TSUKINO, TAKASHI HAJIRO, AKIHIKO IKEDA, and TAKATERU IZUMI

Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan

The purpose of the present study was to compare the characteristics of three different exercise tests in evaluating the effects of oxitropium bromide on exercise performance. Thirty-eight males with stable chronic obstructive pulmonary disease (COPD) (FEV₁ = 40.8 ± 16.5% predicted; mean ± SD) completed randomized, double-blind, placebo-controlled, crossover studies for each exercise test. The exercise tests were performed 60 min after the inhalation of either oxitropium bromide 400 µg or placebo. The patients performed 6-min walking tests (6MWT) on Days 1 and 2, progressive cycle ergometry (PCE) on Days 3 and 4, and cycle endurance tests at 80% of the maximal workload of PCE on Days 5 and 6. Spirometry was conducted before and at 45 and 90 min after the inhalation. Oxitropium bromide significantly increased FEV₁ as compared with placebo. Oxitropium bromide increased the endurance time significantly, by 19% (p < 0.001), and caused a small but significant increase in the 6-min walking distance by 1% (p < 0.05), but induced no significant increase in maximal oxygen consumption ( O₂max) in PCE. The responses in these three exercise tests were different, and we conclude that the endurance test was the most sensitive in detecting the effects of inhaled anticholinergic agents on exercise performance in patients with stable COPD. An endurance procedure may be performed to detect clinical changes in evaluating the effects of oxitropium bromide on exercise performance.

This article has been cited by other articles:

				D. E. O'Donnell, J. Travers, K. A. Webb, Z. He, Y-M. Lam, A. Hamilton, S. Kesten, F. Maltais, and H. Magnussen Reliability of ventilatory parameters during cycle ergometry in multicentre trials in COPD Eur. Respir. J., October 1, 2009; 34(4): 866 - 874. [Abstract] [Full Text] [PDF]

				L. Puente-Maestu, F. Villar, J. de Miguel, W. W. Stringer, P. Sanz, M. L. Sanz, J. Garcia de Pedro, and Y. Martinez-Abad Clinical relevance of constant power exercise duration changes in COPD Eur. Respir. J., August 1, 2009; 34(2): 340 - 345. [Abstract] [Full Text] [PDF]

				A. J. Peacock, R. Naeije, N. Galie, and L. Rubin End-points and clinical trial design in pulmonary arterial hypertension: have we made progress? Eur. Respir. J., July 1, 2009; 34(1): 231 - 242. [Abstract] [Full Text] [PDF]

				V. V. McLaughlin, D. B. Badesch, M. Delcroix, T. R. Fleming, S. P. Gaine, N. Galie, J. S. R. Gibbs, N. H. Kim, R. J. Oudiz, A. Peacock, et al. End Points and Clinical Trial Design in pulmonary arterial hypertension. J. Am. Coll. Cardiol., June 30, 2009; 54(1 Suppl): S97 - 107. [Abstract] [Full Text] [PDF]

				B. J. Whipp and S. A. Ward Quantifying intervention-related improvements in exercise tolerance Eur. Respir. J., June 1, 2009; 33(6): 1254 - 1260. [Abstract] [Full Text] [PDF]

				J. A. Murray, L. A. Waterman, J. Ward, J. C. Baird, and D. A. Mahler Perceptual and Physiologic Responses During Treadmill and Cycle Exercise in Patients With COPD Chest, February 1, 2009; 135(2): 384 - 390. [Abstract] [Full Text] [PDF]

				R. Casaburi Boosting the Effectiveness of Rehabilitative Exercise Training Am. J. Respir. Crit. Care Med., April 15, 2008; 177(8): 805 - 806. [Full Text] [PDF]

				C. Brouillard, V. Pepin, J. Milot, Y. Lacasse, and F. Maltais Endurance shuttle walking test: responsiveness to salmeterol in COPD Eur. Respir. J., March 1, 2008; 31(3): 579 - 584. [Abstract] [Full Text] [PDF]

				S. Jenkins Which is the best exercise test to assess therapeutic intervention in COPD? Chronic Respiratory Disease, February 1, 2008; 5(1): 3 - 5. [PDF]

				M. Cazzola, W. MacNee, F. J. Martinez, K. F. Rabe, L. G. Franciosi, P. J. Barnes, V. Brusasco, P. S. Burge, P. M. A. Calverley, B. R. Celli, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers Eur. Respir. J., February 1, 2008; 31(2): 416 - 469. [Abstract] [Full Text] [PDF]

				D. E. O'Donnell, R. B. Banzett, V. Carrieri-Kohlman, R. Casaburi, P. W. Davenport, S. C. Gandevia, A. F. Gelb, D. A. Mahler, and K. A. Webb Pathophysiology of Dyspnea in Chronic Obstructive Pulmonary Disease: A Roundtable Proceedings of the ATS, May 1, 2007; 4(2): 145 - 168. [Abstract] [Full Text] [PDF]

				D. J. Serisier, A. D. Coates, and S. D. Bowler Effect of Albuterol on Maximal Exercise Capacity in Cystic Fibrosis Chest, April 1, 2007; 131(4): 1181 - 1187. [Abstract] [Full Text] [PDF]

				M D L Morgan and S J Singh Assessing the exercise response to a bronchodilator in COPD: time to get off your bike? Thorax, April 1, 2007; 62(4): 281 - 283. [Full Text] [PDF]

				V. Pepin, J. Brodeur, Y. Lacasse, J. Milot, P. LeBlanc, F. Whittom, and F. Maltais Six-minute walking versus shuttle walking: responsiveness to bronchodilation in chronic obstructive pulmonary disease Thorax, April 1, 2007; 62(4): 291 - 298. [Abstract] [Full Text] [PDF]

				P. Palange, S. A. Ward, K-H. Carlsen, R. Casaburi, C. G. Gallagher, R. Gosselink, D. E. O'Donnell, L. Puente-Maestu, A. M. Schols, S. Singh, et al. Recommendations on the use of exercise testing in clinical practice Eur. Respir. J., January 1, 2007; 29(1): 185 - 209. [Abstract] [Full Text] [PDF]

				D. A. Mahler, L. A. Waterman, J. Ward, and J. C. Baird Responsiveness of Patient-Reported Breathlessness During Exercise in Persistent Asthma Chest, January 1, 2007; 131(1): 195 - 200. [Abstract] [Full Text] [PDF]

				A. L. P. Albuquerque, L. E. Nery, D. S. Villaca, T. Y. S. Machado, C. C. Oliveira, A. T. Paes, and J. A. Neder Inspiratory fraction and exercise impairment in COPD patients GOLD stages II-III Eur. Respir. J., November 1, 2006; 28(5): 939 - 944. [Abstract] [Full Text] [PDF]

				D. E. O'Donnell, F. Sciurba, B. Celli, D. A. Mahler, K. A. Webb, C. J. Kalberg, and K. Knobil Effect of Fluticasone Propionate/Salmeterol on Lung Hyperinflation and Exercise Endurance in COPD. Chest, September 1, 2006; 130(3): 647 - 656. [Abstract] [Full Text] [PDF]

				S A Ward Exercise testing needs to be comprehensive Chronic Respiratory Disease, April 1, 2006; 3(2): 109 - 109. [PDF]

				V. Pepin, D. Saey, F. Whittom, P. LeBlanc, and F. Maltais Walking versus Cycling: Sensitivity to Bronchodilation in Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., December 15, 2005; 172(12): 1517 - 1522. [Abstract] [Full Text] [PDF]

				W. Vincken Bronchodilator treatment of stable COPD: long-acting anticholinergics Eur. Respir. Rev., September 1, 2005; 14(94): 23 - 31. [Abstract] [Full Text] [PDF]

				T. Oga, K. Nishimura, M. Tsukino, S. Sato, T. Hajiro, and M. Mishima Exercise Capacity Deterioration in Patients With COPD: Longitudinal Evaluation Over 5 Years Chest, July 1, 2005; 128(1): 62 - 69. [Abstract] [Full Text] [PDF]

				T. Troosters, R. Casaburi, R. Gosselink, and M. Decramer Pulmonary Rehabilitation in Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., July 1, 2005; 172(1): 19 - 38. [Full Text] [PDF]

				T. Higenbottam Pulmonary Hypertension and Chronic Obstructive Pulmonary Disease: A Case for Treatment Proceedings of the ATS, April 1, 2005; 2(1): 12 - 19. [Abstract] [Full Text] [PDF]

				R. J. Oudiz and K. Wasserman Clinical efficacy of sildenafil in primary pulmonary hypertension J. Am. Coll. Cardiol., December 7, 2004; 44(11): 2256 - 2256. [Full Text] [PDF]

				B.K.S. Sastry and C. Narasimhan Reply J. Am. Coll. Cardiol., December 7, 2004; 44(11): 2256 - 2257. [Full Text] [PDF]

				D.E. O'Donnell, N. Voduc, M. Fitzpatrick, and K.A. Webb Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease Eur. Respir. J., July 1, 2004; 24(1): 86 - 94. [Abstract] [Full Text] [PDF]

				D.E. O'Donnell, T. Fluge, F. Gerken, A. Hamilton, K. Webb, B. Aguilaniu, B. Make, and H. Magnussen Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD Eur. Respir. J., June 1, 2004; 23(6): 832 - 840. [Abstract] [Full Text] [PDF]

				K.-C. Ong, A.-C. Kor, W.-F. Chong, A. Earnest, and Y.-T. Wang Effects of Inhaled Furosemide on Exertional Dyspnea in Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., May 1, 2004; 169(9): 1028 - 1033. [Abstract] [Full Text] [PDF]

				T. Oga, K. Nishimura, M. Tsukino, S. Sato, T. Hajiro, and M. Mishima A Comparison of the Effects of Salbutamol and Ipratropium Bromide on Exercise Endurance in Patients With COPD Chest, June 1, 2003; 123(6): 1810 - 1816. [Abstract] [Full Text] [PDF]

				T. Oga, K. Nishimura, M. Tsukino, S. Sato, and T. Hajiro Analysis of the Factors Related to Mortality in Chronic Obstructive Pulmonary Disease: Role of Exercise Capacity and Health Status Am. J. Respir. Crit. Care Med., February 15, 2003; 167(4): 544 - 549. [Abstract] [Full Text] [PDF]

				ATS/ACCP Statement on Cardiopulmonary Exercise Testing Am. J. Respir. Crit. Care Med., January 15, 2003; 167(2): 211 - 277. [Full Text] [PDF]

				S. V. Culpitt, C. de Matos, R. E. Russell, L. E. Donnelly, D. F. Rogers, and P. J. Barnes Effect of Theophylline on Induced Sputum Inflammatory Indices and Neutrophil Chemotaxis in Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., May 15, 2002; 165(10): 1371 - 1376. [Abstract] [Full Text] [PDF]

				M. J. TOBIN Chronic Obstructive Pulmonary Disease, Pollution, Pulmonary Vascular Disease, Transplantation, Pleural Disease, and Lung Cancer in AJRCCM 2000 Am. J. Respir. Crit. Care Med., November 15, 2001; 164(10): 1789 - 1804. [Full Text] [PDF]

				M.L. Ayers, R. Mejia, J. Ward, T. Lentine, and D.A. Mahler Effectiveness of salmeterol versus ipratropium bromide on exertional dyspnoea in COPD Eur. Respir. J., June 1, 2001; 17(6): 1132 - 1137. [Abstract] [Full Text] [PDF]